×
About 6,250 results

ALLMedicine™ Cutaneous Melanoma Center

Research & Reviews  2,151 results

Adapted Physical Activity Protocol for Lower Limb Functional and Strength Recovery in a...
https://doi.org/10.3390/ijerph19159590
International Journal of Environmental Research and Publi... Carretti G, Mirandola D et. al.

Aug 13th, 2022 - Adapted physical activity (APA) can improve psychophysical wellbeing and quality of life (QoL) in cancer survivors, a vulnerable population requiring a global management, especially during the recent pandemic. On this basis, we investigated for th...

Pan-Cancer Analysis of Voltage-Dependent Anion Channel (VDAC1) as a Cancer Therapeutic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357804
Disease Markers; Wang Z, Cheng Y et. al.

Aug 13th, 2022 - The voltage-dependent anion channel 1 (VDAC1), a pore protein located in the outer mitochondrial membrane, has been confirmed to be related to cancer in cell or animal evidence. However, there is no available pan-cancer analysis of VDAC1. Herein, ...

Lentigo Maligna Melanoma
https://emedicine.medscape.com/article/279839-overview

Aug 11th, 2022 - Overview Lentigo maligna is a subtype of melanoma in situ that is characterized by an atypical proliferation of melanocytes within the basal epidermis; lentigo maligna that invades the dermis is termed lentigo maligna melanoma. [1] Lentigo maligna...

Lentigo Maligna Melanoma
http://emedicine.medscape.com/article/279839-overview

Aug 11th, 2022 - Overview Lentigo maligna is a subtype of melanoma in situ that is characterized by an atypical proliferation of melanocytes within the basal epidermis; lentigo maligna that invades the dermis is termed lentigo maligna melanoma. [1] Lentigo maligna...

Lentigo Maligna Melanoma
https://emedicine.medscape.com/article/279839-print

Aug 11th, 2022 - Lentigo maligna is a subtype of melanoma in situ that is characterized by an atypical proliferation of melanocytes within the basal epidermis; lentigo maligna that invades the dermis is termed lentigo maligna melanoma.[1] Lentigo maligna melanoma ...

see more →

Guidelines  9 results

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - ...
https://doi.org/10.1016/j.ejca.2022.04.018
European Journal of Cancer (Oxford, England : 1990); Garbe C, Amaral T et. al.

May 28th, 2022 - A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recomm...

SEOM clinical guideline for the management of cutaneous melanoma (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057998
Clinical & Translational Oncology : Official Publication ... Majem M, Manzano JL et. al.

Mar 3rd, 2021 - Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of t...

Systemic Therapy for Melanoma: ASCO Guideline.
https://doi.org/10.1200/JCO.20.00198
Journal of Clinical Oncology : Official Journal of the Am... Seth R, Messersmith H et. al.

Apr 2nd, 2020 - To provide guidance to clinicians regarding the use of systemic therapy for melanoma. ASCO convened an Expert Panel and conducted a systematic review of the literature. A systematic review, one meta-analysis, and 34 additional randomized trials we...

Guidelines of care for the management of primary cutaneous melanoma.
https://doi.org/10.1016/j.jaad.2018.08.055
Journal of the American Academy of Dermatology; Swetter SM, Tsao H et. al.

Nov 6th, 2018 - The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Derm...

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immun...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977556
Journal for Immunotherapy of Cancer; Sullivan RJ, Atkins MB et. al.

Jun 1st, 2018 - Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patien...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  131 results

IFx-Hu2.0 Expanded Access Program
https://clinicaltrials.gov/ct2/show/NCT04853602

Aug 9th, 2022 - Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or advanced cutaneous squam...

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
https://clinicaltrials.gov/ct2/show/NCT03655756

Aug 8th, 2022 - Six male and/or female adult patients (greater than or equal to 18 years old), of any ethnicity and race, with unresectable stage III or stage IV cutaneous melanoma with accessible lesions, will be eligible for enrollment and treatment with IFx-Hu...

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
https://clinicaltrials.gov/ct2/show/NCT04830124

Aug 3rd, 2022 - This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
https://clinicaltrials.gov/ct2/show/NCT05315258

Aug 2nd, 2022 - TebeMRD is an unblinded non-randomised, open labelled, safety and efficacy study involving 2 patient cohorts: A: Cutaneous melanoma with molecular relapsed disease (MRD) B: Uveal melanoma with MRD Approximately 850 patients (600 cutaneous melanoma...

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
https://clinicaltrials.gov/ct2/show/NCT03860883

Aug 1st, 2022 - This study will determine whether there is a difference in disease-free survival rates for patients with primary cutaneous melanoma with Breslow thickness > 2mm or 1-2mm with ulceration (pT2b-pT4b, AJCC 8th edition), treated with either a 1cm exci...

see more →

News  208 results

Study explores gender differences in pediatric melanoma
https://www.mdedge.com/dermatology/article/256113/pediatrics/study-explores-gender-differences-pediatric-melanoma
Doug Brunk

Jul 8th, 2022 - INDIANAPOLIS – Among children and adolescents diagnosed with melanoma, females had higher rates of superficial spreading disease, while males were more frequently affected by nodular melanoma. In addition, male gender was independently associated.

Study Explores Gender Differences in Pediatric Melanoma
https://www.medscape.com/viewarticle/976785

Jul 8th, 2022 - INDIANAPOLIS – Among children and adolescents diagnosed with melanoma, females had higher rates of superficial spreading disease, while males were more frequently affected by nodular melanoma. In addition, male gender was independently associated ...

BRAF V600E Expression in Primary Melanoma and Its Association With Death: A Population-Based, Retrospective, Cross-Sectional Study
https://www.mdedge.com/dermatology/article/254405/melanoma/braf-v600e-expression-primary-melanoma-and-its-association-death
Jamison A. Harvey, MD, Julia S. Lehman, MD et. al.

May 6th, 2022 - Approximately 50% of melanomas contain BRAF mutations, which occur in a greater proportion of melanomas found on sites of intermittent sun exposure. 1BRAF-mutated melanomas have been associated with high levels of early-life ambient UV exposure, es.

Administration of RP1 Through Intratumoral Injection Offers Unique Advantages in Melanoma Treatment
https://www.onclive.com/view/administration-of-rp1-through-intratumoral-injection-offers-unique-advantages-in-melanoma-treatment

Apr 26th, 2022 - Oncolytic immunotherapy with talimogene laherparepvec (T-VEC; Imlygic) and vusolimogene oderparepvec (RP1) has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration, according to Nik...

Global melanoma incidence high and on the rise
https://www.mdedge.com/dermatology/article/253470/melanoma/global-melanoma-incidence-high-and-rise
Neil Osterweil

Apr 5th, 2022 - Even by cautious calculations, the worldwide incidence of cutaneous melanoma is high and predicted to rise sharply over the next 2 decades, cancer epidemiologists warn. An estimated 325,000 people worldwide received a new diagnosis of cutaneous me.

see more →